High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients
- 21 February 2017
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 114 (10), 2544-2549
- https://doi.org/10.1073/pnas.1612229114
Abstract
Malignant pleural effusion (MPE), the presence of malignant cells in pleural fluid, is often the first sign of many cancers and occurs in patients with metastatic malignancies. Accurate detection of tumor cells in pleural fluid is crucial because the presence of MPE denotes an advanced stage of disease and directs a switch in clinical managements. Cytology, as a traditional diagnostic tool, has limited sensitivity especially when tumor cells are not abundant, and may be confounded by reactive mesothelial cells in the pleural fluid. We describe a highly sensitive approach for rapid detection of metabolically active tumor cells in MPE via exploiting the altered glucose metabolism of tumor cells relative to benign cells. Metabolically active tumor cells with high glucose uptake, as evaluated by a fluorescent glucose analog (2-NBDG), are identified by high-throughput fluorescence screening within a chip containing 200,000 addressable microwells and collected for malignancy confirmation via single-cell sequencing. We demonstrate the utility of this approach through analyzing MPE from a cohort of lung cancer patients. Most candidate tumor cells identified are confirmed to harbor the same driver oncogenes as their primary lesions. In some patients, emergence of secondary mutations that mediate acquired resistance to ongoing targeted therapies is also detected before resistance is manifested in the clinical imaging. The detection scheme can be extended to analyze peripheral blood samples. Our approach may serve as a valuable complement to cytology in MPE diagnosis, helping identify the driver oncogenes and resistance-leading mutations for targeted therapies.Keywords
Funding Information
- National Natural Science Foundation of China (81401880)
- National Natural Science Foundation of China (81373621)
- HHS | NIH | National Cancer Institute (1U54 CA199090-01)
This publication has 29 references indexed in Scilit:
- In vivo imaging of epileptic activity using 2-NBDG, a fluorescent deoxyglucose analogJournal of Neuroscience Methods, 2012
- A Novel Platform for Detection of CK+ and CK− CTCsCancer Discovery, 2011
- Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissueBiomedical Optics Express, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell linesBreast Cancer Research and Treatment, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell LinesPLOS ONE, 2009
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerThe New England Journal of Medicine, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004